- Mechanism: A new lithium-based compound, AL001, is being explored for its neuroprotective effects in dementia. Lithium has long been known for its benefits in mood stabilization but, at high doses, can cause side effects like kidney damage. This newer formulation uses microdosing techniques, reducing side effects while still promoting neurogenesis and reducing tau and amyloid-beta accumulation—two hallmarks of Alzheimer’s disease.
- Results: In preclinical studies, AL001 has shown the potential to prevent cognitive impairment and memory loss in animal models. The microdose approach minimizes adverse effects commonly associated with lithium therapy.
- Current Stage: Phase 2 clinical trials are underway to evaluate its efficacy in humans